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Background: Granulosa tumors were described for the first time in 1855 by Rokitansky. These tumors are
malignancies with a relatively favorable prognosis. They are characterized by a prolonged natural history and a
tendency to late recurrences. The aim of this study is to investigate the epidemiological and pathological
characteristics of granulosa cell tumors and to investigate the prognosis factor for recurrences.
Methods: The clinical data of patients who were treated in the period from January 2003 to December 2010 at the
National Institute of Oncology in Rabat, Morocco for adult granulosa cell tumors of the ovary were investigated
retrospectively. Data for age, clinical manifestation, imaging, diagnosis and treatment of the patients were reviewed
and analyzed. Post-operative histology was obtained for all patients.
Results: Twenty-seven cases were retrieved. The median patient age was 53 years. The most common clinical
manifestations at diagnosis were abdominal pain and vaginal bleeding. Mean tumor size was 14 cm.
The majority of patients had stage I (63%, n = 17), while (18,5%, n = 5) had stage III, (7.4%, n = 2) had stage IV,
and (11%, n = 3) of patients had an unknown stage.
In the follow-up period (median = 63.44 months), five (18.51%) patients relapsed. The median time to relapse was
41.8 months, (range: 18 to 62 months).
Conclusions: Granulosa cell tumor of the ovary is an uncommon neoplasm. The adult form progresses slowly and
often is diagnosed in an early stage of disease. Surgery is indicated. A prolonged post-therapeutic follow-up is
necessary because of the risk of recurrences, late and exceptional for the adult form.
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Granulosa cell tumors are very rare ovarian malignan-
cies; they represent 2 to 3% of all ovarian cancers and
mainly occur within the adult population [1]. They arise
from sex cord tumors and stroma. In comparison to epi-
thelial ovarian cancers, they are characterized by a good
prognosis [2]. There are two histological forms: an adult
form (95%) [3] and a juvenile form (5%), which is char-
acterized by occurrence at an early age, with more pro-
nounced signs of malignancy and an increased risk of
recurrence [3,4].
These tumors have a particular clinical, histological
and evolutive profile, and may reoccur up to 40 years
after diagnosis [5].* Correspondence: sakina.sekkate@yahoo.fr
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reproduction in any medium, provided the orComplete surgical resection is the mainstay of treatment,
particularly in the case of early stage patients. Surgery has
to be combined with platinum-based chemotherapy for ad-
vanced stages [6].
The aim of this study is to report the epidemiologic,
anatomo-clinical characteristics and to determine the
prognostic factors of survival.
Methods
Clinical data
This is a retrospective study of patient data originally
collected between January 2003 and December 2010. A
total of 27 patients were diagnosed with granulosa cell
tumors during that time period by the Department of
Clinical Oncology, in the National Institute of Oncology
based in Rabat, Morocco.
The recorded information includes, age, parity, meno-
pausal status, symptoms, diameters of tumors, stage ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the patients
Characteristics (n = 27) Number of patients (%)
Age, median (years) 53
➢ Third decade of life 1 (4%)
➢ Fourth decade of life 3 (11%)
➢ Fifth decade of life 8 (30%)
➢ Sixth decade of life 5 (18%)
➢ Seventh decade of life 6 (22%)
➢ Eighth decade of life 4 (15%)
Symptoms at diagnosis
➢ Abdominal pain 16 (59%)
➢ Abdominal distention 12 (44%)
➢ Postmenopausal bleeding 5 (19%)
➢ Intermenstrual bleeding 10 (37%)
➢ Amenorrhea 3 (11%)
Tumor size (mean size: 14 cm)
➢ ≤10 cm 8 (30%)
➢ >10 cm 19 (70%)
Stage
➢ I: 17 (63%)
Ia 12 (44%)
Ic 5 (19%)
➢ III 5 (18.5%)
IIIa 1 (4%)
IIIc 4 (15%)
➢ IV 2 (7.5%)
➢ Unknown 3 (11%)
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months, recurrence and mortality.
Follow-up
Patients were followed up until November 2012.
Statistical analyses
The statistical analyses were done using SPSS 10.0
software. Department of statistics, National Institute of
Oncology, Rabat, Morocco.
In this analysis, clinical data is expressed in percentages.
Consent and statement of ethical approval
As the treatment of each patient was decided by the
medical staff of the centre, oral consent was obtained
from the subjects and was approved by the institutional
review boards of the National Institute of Oncology,
Cancer Centre in Rabat. This study was approved by the




During the period from January 2003 through December
2010, 27 patients underwent surgery for the adult form
of granulosa cell tumors. The mean age of the patients
was 53 years.
For 70% of the patients, the tumor occurred between
the fifth and seventh decades. The mean parity was 3.14,
and 41% of the patients (n = 11) were menopausal.
A total of 59% of the patients (n = 16) presented abdom-
inal pain at diagnosis and also presented with vaginal
bleeding as follows: intermenstrual bleeding (37%, n = 10),
postmenopausal bleeding (19%, n = 5).
Other symptoms included abdominal distension (44%
n = 12) and amenorrhea (11%, n = 3).
The average tumor size was 14 cm (range: 7 to 30 cm).
A summary of patient characteristics is presented below
in Table 1.
Treatment
Twenty-two patients (81%) underwent hysterectomy with
bilateral salpingo-oophorectomy with optimal resection
(R0), omentectomy, +/− lymphadenectomy and multiple
biopsy. Three patients (11%) had unilateral oophorectomy,
and two patients (7.4%) had debulking surgery.
Thirteen patients had endometrial biopsies. The re-
sults were as follows: four were negative, six were
hyperplasic, and three were atrophic.
Eight patients received adjuvant treatment (four: bleo-
mycin etoposide, cisplatin (BEP); one: bleomycin vepeside
cisplatin (BVP); one: endoxan cisplatin; one: paclitaxel cis-
platin; one: tamoxifene), and two patients received chemo-
therapy for metastatic disease (one: BVP; one: BEP).Staging
The staging breakdown was as follows: stage I (63%,
n = 17), stage III (18.5%, n = 5), and stage IV (7.5%, n = 2).
For the remaining 11% of patients (n = 3), the stage
was unknown.
Survival
During the follow-up (median: 63.44 months), five pa-
tients (18.5%) relapsed, and four of those patients died
of the disease (Figure 1).
Patient characteristics for those patients with recurrent
disease are shown below in Table 2.
The median time to relapse was 41.8 months, (range:
18 to 62 months).
The overall 5-year survival and 9-year survival rates
for all stages were 91.3% and 77.3%, respectively
(Figure 2).
Following univariate Cox regression modeling, survival
appears to be dependent on the stage, as it is much bet-
ter in localized stages (P = 0.05) (Figure 3).
Other parameters considered in this study did not sig-
nificant influence survival.
Figure 1 Management and outcomes of patients.
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Granulosa cell tumors are very rare. They were de-
scribed for the first time in 1855 by Rokitansky [7], who
described them according to their appearance near the
granulosa cells of ovarian follicles. They occur in the
peri- and postmenopausal period with peak prevalence
in patients aged 50 to 55 years. The other peak fre-
quency corresponds to the prepubertal age [8,9].
The symptoms are various: abdominal pain (30 to 50%),
abdominal distension related to mass effect and hormonal
events (41%) such as irregular menstruation, intermenstrual
bleeding, postmenopausal bleeding or amenorrhea [10].
However, for those cases in which the patient is
asymptomatic, the clinical exam is very important [11].
Endocrine manifestations are noted in 66% of the pa-
tients. These manifestations are related to estrogen se-
cretion of the tumor [12].
This explains why the granulosa cell tumors are fre-
quently associated with endometrial hyperplasia (4 to 10%)
or to endometrial adenocarcinoma (5 to 35%) [4,9,10].Table 2 Characteristics of patients with recurrent disease
Case Age (years) Stage Size of tumor (cm) Primary treatment
1 73 IIIc 20 Deb Sur + CMT
2 64 IIIa 20 Com Sur + CMT
3 47 IV 15 Com Sur + CMT
4 76 Ia 10 Com Sur + Horm
5 41 IIIc 11 Com Sur + CMT
Com Sur, complete surgery, CMT chemotherapy, Deb sur debulking surgery, Horm hTherefore, endometrial and cervical biopsies are essen-
tial to define the therapeutic strategy.
The juvenile form can be characterized by the pres-
ence of pseudopuberty (50% depending on the series)
[13,14], and galactorrhea may complete the clinical pres-
entation. The mechanism is not clearly established [9].
Radiologicaly speaking, the granulosa cell tumor presents
as a solid component with multicystic appearance, with a
median diameter of 12 cm (range: 1 to 30 cm) [15,16].
The imaging appearances of the two forms of granulosa
cells tumors are similar.
The same clinical and radiological data were noted in
the patients from our study.
The diagnosis is confirmed by histological analyses. The
adult form includes five subtypes, among which the most
common subtype - microfollicular - is characterized by
Call-Exner bodies and cores “coffee bean” [17,18].
In the juvenile form, the architecture is often lobu-
lated, Call-Exner bodies are rare, and the signs of luteini-






ormonal therapy, Perit peritoneum.
Figure 2 Overall survival at 5 years and 9 years for all patients.
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these cells are vimentin, CD 99 and alpha inhibin.
The serum tumor markers are estradiol, inhibin, and
anti-Müllerian hormone. Cancer antigen 125 (CA-125)
is not correlated to the tumor progression [18].
Kalfa et al. [19] identified a mutation FOXL2 (tran-
scription factor gene) in the majority of granulosa cell
tumors, particularly in adult form. This FOXL2 could be
the next target for use in treatment.
Yoo et al. [20] also identified mutations of genes Fas,
FLIP and Bcl-2 related to alterations of apoptosis.
The principal differential diagnoses of granulosa cell
tumors are: endometrioid carcinoma, stromal sarcoma,
carcinoid tumors and adenocarcinoma [21].
Various factors determine the prognosis. The most im-
portant prognostic variable is the stage.Figure 3 Overall survival by stage.The survival rates at 5 years and 10 years were reported
by Malmstrom et al. [2], 94% and 88%, respectively, for
stage I, and decreasing to 44% for stage II and III.
Wu et al. [22] also reported their results about sur-
vival for 100 patients with granulosa cell tumors; sur-
vival rates at 5 years and 10 years were 98% and 96%,
respectively, for stage I and were 70% and 60%, respect-
ively, for stage II. The recurrence rate is also related to
the stage [23].
The results of Ahyan’s study of 80 patients with granulosa
cell tumors, revealed recurrence rates of 5.4%, 21% and
40% for stage I, stage II and stage III, respectively [24].
The prognostic value of stage was also noted in our
study.
An age younger than 40 years is associated with a bet-
ter prognosis, but the opinions differ [4,9].
In Ahyan’s trial, patients aged below 60 years had bet-
ter mean time of survival (154.6 versus 89.2 months,
P = 0.015) [24].
For most authors, larger tumor size is associated with
a poor prognosis, particularly tumors that measured
more than 10 cm [10,25].
Residual disease after surgery is also another prognosis
factor. In Sehouli’s trial [26], the survival was lower for
patients with postoperative residual disease.
The number of mitoses is also a recognized prognostic
factor and there is an inverse relationship between sur-
vival and the number of mitoses [8,17].
Many studies, including the Schumer trial [27], proved
that tumor rupture is also a prognosis factor.
Expressions of P53 mutations are common and may
be associated with poor prognosis [28,29].
Ala Fossi et al. [30] noted that survival of patients with
no mutations of P53 was 10 times higher than for pa-
tients with mutations.
Concerning inhibin, its value may be correlated to the
tumor mass, with an increased level of inhibin in serum
preceding clinical relapse [31,32].
The mainstay of treatments are complete surgery (hys-
terectomy, bilateral salpingoopherectomy) with staging
for early stage and debulking surgery for advanced stage
or recurrent disease [33].
There is no standard regimen concerning adjuvant treat-
ment, but it is usually recommended for the adult form of
granulosa cell tumors and for patients at high risk [2,23,27].
The most used chemotherapy regimen is a BVP (bleo-
mycin, vinblastine, and cisplatin) or a BEP regimen,
which substitutes etoposide for vinblastine [21].
The hormonal therapy based on megestrol and LHRH
(luteinizing hormone-releasing hormone) agonists also
lead to good responses, particularly for recurrent disease
cases [34,35].
Rico et al. [36] demonstrated an increase in Mtor
(mammalian target of rapamycin) deregulation by using
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Mtor may be beneficial to women with granulosa cell tu-
mors. More studies will be necessary.
For results of survival, the overall survival (approxi-
mately 90% at 5 years for early stage) is good, because
most tumors are diagnosed early [16,22].
The evolution of adult granulosa cell tumors is slow and
recurrences are rare and often delayed. These tumors can
reoccur after a free interval of 6 to 23 years [10,21].
Conclusions
Granulosa cell tumor of the ovary is an uncommon neo-
plasm. An important prognosis factor is stage at initial
diagnosis. Due to the rarity of this disease, several pro-
spective studies must be reported to establish a consensus.
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